Tarsus Pharmaceuticals, Inc. TARS

TARS Company Overview

Tarsus Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on the development and commercialization of therapies for diseases with significant unmet medical need, particularly in ophthalmology and immunology. The company operates primarily in the prescription pharmaceutical industry and is best known for developing treatments targeting inflammatory and parasitic conditions affecting the eye. Tarsus’ commercial and clinical strategy has centered on leveraging targeted therapeutic approaches for diseases that have historically lacked FDA-approved treatment options.

The company’s primary revenue driver is XDEMVY (lotilaner ophthalmic solution), an FDA-approved treatment for Demodex blepharitis, a common eyelid disease associated with Demodex mite infestation. Tarsus has also advanced pipeline programs investigating the use of lotilaner and related compounds in additional therapeutic indications, including dermatologic and ophthalmic conditions. The company was founded in 2016 and evolved from a clinical-stage biotechnology company into a commercial-stage pharmaceutical business following the U.S. regulatory approval and launch of XDEMVY in 2023. Public filings and investor disclosures indicate that the company’s strategic positioning is based on first-mover advantage in underserved disease categories and specialization in targeted anti-parasitic therapeutics.